

Form PTO-1449 (modified)

Atty. Docket No.  
RIOS:004USC2Serial No.  
10/667,534

List of Patents and Publications for Applicant's

Applicant  
Adan Rios

INFORMATION DISCLOSURE STATEMENT

Filing Date:  
September 22, 2003Group:  
Unknown 1648

(Use several sheets if necessary)

U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,849,475	12/15/98	Rovinski <i>et al.</i>	435	5	5/30/95
	A2	5,919,458	7/6/99	Aldovini <i>et al.</i>	424	188.1	6/7/95
	A3	6,017,543	1/25/00	Salk <i>et al.</i>	424	208.1	6/5/95
	A4	6,080,408	6/27/00	Rovinski <i>et al.</i>	424	188.1	6/7/95

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
✓	C1	"Aronex HIV inhibitor nears patent issuance," <i>Reuters NewMedia, Inc.</i> , February 23, 1996, Abstract.
✓	C2	"Aronex reports preliminary clinical results on its HIV integrase inhibitor, zintevir (TM)," <i>PR Newswire</i> , November, 12, 1996, Abstract.
✓	C3	Ada, "An Immunologist's View of HIV Infection," <i>Textbook of AIDS Medicine</i> , Chapter 6, pp. 77-87, Brothier <i>et al.</i> , eds., Williams & Wilkins, Baltimore, MD, 1994.
✓	C4	Ada, "Modern vaccines, the immunological principles of vaccination," <i>The Lancet</i> , 335:523-526, 1990.
✓	C5	Albert, <i>et al.</i> , "Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs," <i>Nature</i> , 392:86-89, 1998.
✓	C6	Aldrovandi <i>et al.</i> , "The SCID-hu mouse as a model for HIV-1 infection," <i>Nature</i> , 363:732-736, 1993.
✓	C7	Amadori <i>et al.</i> , "The hu-PBL-SCID mouse in human lymphocyte function and lymphomagenesis studies: achievements and caveats," <i>Semin Immunol</i> , 8:249-254, 1996.

25356361.1

EXAMINER:

DATE CONSIDERED:

6/10/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

RIOS:004USC2

10/667,534

List of Patents and Publications for Applicant's

Applicant

Adan Rios

INFORMATION DISCLOSURE STATEMENT

Filing Date:

September 22, 2003

Group:

Unknown 1648

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
7	C8	Baba <i>et al.</i> , "Pathogenicity of live, attenuated hiv after mucosal infection of neonatal macaques," <i>Science</i> , 267:1820-1825, 1995.
*	C9	Bachmann and Zinkernagel, "Neutralizing antiviral b cell responses," <i>Annu. Rev. Immunol.</i> , 15:235-270, 1997.
*	C10	Balter, "A cluster of Europe's aids research stars," <i>Science</i> , 280:1862, 1998c.
*	C11	Balter, "Duo brings hope of immune restoration," <i>Science</i> , 280:1861, 1998b.
+	C12	Balter, "Global program struggles to stem the flood of new cases," <i>Science</i> , 280:1863-1864, 1998d.
+	C13	Balter, "HIV incidence: 'more serious than we imagined'," <i>Science</i> , 280:1864, 1998e.
+	C14	Balter, "Modest briton stirs up storm with views on role of CTLs," <i>Science</i> , 280:1860-1861, 1998a.
*	C15	Balter, "T cell production slowed, not exhausted?" <i>Science</i> , 283(5400):305-306, 1999.
*	C16	Baltimore, "Lessons from people with nonprogressive hiv infection," <i>The New England J. of Medi.</i> , 332:259-260, 1995.
*	C17	Banchereau and Steinman, "Dendritic cells and the control of immunity," <i>Nature</i> , 392:245-252, 1998.
+	C18	Barnard <i>et al.</i> , "The thiocarboxanilide nonnucleoside uc781 is a tight-binding inhibitor of hiv-1 reverse transcriptase," <i>Biochem.</i> , 36:7786-7792, 1997.
*	C19	Barr, "Vaccines for HIV, HIV therapeutic vaccines: the next phase," <i>GMHC's Treat. Iss.</i> , Vol. 7, No. 5, 1993.
*	C20	Bender <i>et al.</i> , "Inactivated influenza virus, when presented on dendritic cells, elicits human cd8 <sup>+</sup> cytolytic t cell responses," <i>J. Exp. Med.</i> , 12:1663-1671, 1995.
*	C21	Berger <i>et al.</i> , "A new classification of HIV-1," <i>Nature</i> , 391:340, 1998.
*	C22	Blauvelt <i>et al.</i> , "Productive infection of dendritic cells by hiv-1 and their ability to capture virus are mediated through separate pathways," <i>The J. of Clin. Invest.</i> , 100:2043-2053, 1997.
*	C23	Bolognesi and Matthews, "Viral envelope fails to deliver?," <i>Nature</i> , 391:638-639, 1998.

25356361.1

EXAMINER:

DATE CONSIDERED:

10/01/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

RIOS:004USC2

10/667,534

List of Patents and Publications for Applicant's

Applicant

Adan Rios

INFORMATION DISCLOSURE STATEMENT

Filing Date:

September 22, 2003

Group:

Unknown 1648

(Use several sheets if necessary)

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 1

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
✕	C24	Bombil <i>et al.</i> , "A promising model of primary human immunization in human-scid mouse," <i>Immunobiology</i> , 195:360-375, 1996 (Abstract).
✕	C25	Borkow <i>et al.</i> , "Chemical barriers to human immunodeficiency virus type 1 (hiv-1) infection: retrovirucidal activity of uc781, a thiocarboxanilide nonnucleoside inhibitor of hiv-1 reverse transcriptase," <i>J. of Virol.</i> , 71:3023-3030, 1997.
✕	C26	Borkow <i>et al.</i> , "Chemical barriers to Human Immunodeficiency Virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase," <i>Journal of Virology</i> 71(4):3023-3030, 1997.
✕	C27	Borkow <i>et al.</i> , "Inhibition of the ribonuclease H and DNA polymerase activities of hiv-1 reverse transcriptase by n-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone," <i>Biochemistry</i> , Abstract, 36(11):3179-3185, 1997.
✕	C28	Bryson <i>et al.</i> , "Clearance of HIV infection in a perinatally infected infant," <i>The New Engl. J. of Med.</i> , 332:833-838, 1995.
✕	C29	Buckheit <i>et al.</i> , "Efficacy pharmacokinetics and in vivo anti-HIV activity of the highly potent oxathiin carboxanilide analog, UC781," <i>Journal of Molecular Medicine</i> 75(7):b212-b213, 1997.
✕	C30	Buckheit <i>et al.</i> , "Efficacy, Pharmacokinetics, and in Vivo Antiviral Activity of UC781, a Highly Potent, Orally Bioavailable Nonnucleoside Reverse Transcriptase Inhibitor of HIV Type 1," <i>Aids Res. and Hu. Retro.</i> , 13:789-796, 1997.
✕	C31	Burr, "Of AIDS and altruism," <i>U.S. Nws. &amp; W. Rpt.</i> , pp. 59-61, April 6, 1998.
✕	C32	Burton and Montefiori, "The antibody response in HIV-1 infection," <i>Aids</i> , 11:S87-S98, 1997.
✕	C33	Cao <i>et al.</i> , "Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection," <i>The New Engl. J. of Med.</i> , 332:201-216, 1995.
✕	C34	Carlson <i>et al.</i> , "Vaccine Protection of Rhesus Macaques Against Simian Immunodeficiency Virus Infection," <i>AIDS Res. and Hum. Retroviruses</i> , 6:1239-1246, 1990.
✕	C35	Cavert and Haase, "A national tissue bank to track HIV eradication and immune reconstitution," <i>Science</i> , 280:1865-1866, 1998.
✕	C36	Cella <i>et al.</i> , "Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells," <i>Nature</i> , 388:782-792, 1997.

25356361.1

EXAMINER:

DATE CONSIDERED:

10/01/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

RIOS:004USC2

10/667,534

List of Patents and Publications for Applicant's

Applicant

Adan Rios

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 22, 2003

Gr up:

Unknown 1648

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/	C37	Chowdhry, "Photoaffinity labeling of biological systems," <i>Ann. Rev. Biochem.</i> , 48:293-325, 1979.
+	C38	Clerici <i>et al.</i> , "HIV-specific t-helper activity in seronegative health care workers exposed to contaminated blood," <i>JAMA</i> , 271:42-46, 1994.
*	C39	Clotet <i>et al.</i> , "Long-term survivors of human immunodeficiency virus type I infection," <i>The New England Journal of Medicine</i> , 332(24):1646-1647, 1995.
+	C40	Cohen <i>et al.</i> , "Characterization of the binding site for nevirapine (bi-rg-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase," <i>J. of Biol. Chem.</i> , 266:14670-14674, 1991.
*	C41	Collins <i>et al.</i> , "HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes," <i>Nature</i> , 391:397-402, 1998.
*	C42	Colonna, "Unmasking the killer's accomplice," <i>Nature</i> , 391:642-644, 1998.
*	C43	Constant and Bottomly, "Induction of TH1 and TH2 CD4 <sup>+</sup> T cell responses: the alternative approaches," <i>Annu. Rev. Immunol.</i> , 15:297-322, 1997.
*	C44	Daniel, <i>et al.</i> , "A role for DNA-PK in retroviral DNA integration," <i>Science</i> , 284:644-647, 1999.
*	C45	DeNoon, "AIDS Therapies: new integrase inhibitor enhances other anti-HIV drugs," <i>AIDSWEEKLY Plus</i> , November 23, 1998, Abstract.
*	C46	Doherty and Zinkernagel, "A Biological role for the major histocompatibility antigens," <i>The Lancet</i> , 1406-1409, 1975.
*	C47	Doherty and Zinkernagel, "The Specificity of the Cell Mediated Immune Defense," <i>The Nobel Assembly at the Karolinska Institute</i> , Press Release October 7, 1996.
*	C48	Dragic <i>et al.</i> , "HIV co-receptors: gateways to the cell," <i>HIV Advances in Research and Therapy</i> , 7(3):2-12, 1997.
+	C49	D'Souza <i>et al.</i> , "Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies," <i>AIDS</i> , 9:867-874, 1995.
*	C50	Dutton <i>et al.</i> , "T cell memory," <i>Annu. Rev. Immunol.</i> , 16:201-223, 1998.
+	C51	Emerman and Malim, "HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology," <i>Science</i> , 280:1880-1884, 1998.

25356361.1

EXAMINER:

DATE CONSIDERED:

10/01/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

RIOS:004USC2

10/667,534

List of Patents and Publications for Applicant's

Applicant

Adan Rios

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 22, 2003

Group:

~~Unknown~~ 1648

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
*	C52	Excler and Plotkin, "The prime-boost concept applied to HIV preventive vaccines," <i>Aids</i> , 11:S127-S137, 1997.
1	C53	Ferrari, "Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers," <i>Proc. Natl. Acad. Sci. USA</i> , 94:1396-1401, 1997.
5	C54	Fletcher <i>et al.</i> , "Carboxanilide derivative non-nucleoside inhibitors of hiv-1 reverse transcriptase interact with different mechanistic forms of the enzyme," <i>Biochem.</i> , 34:4346-4353, 1995.
	C55	Fletcher <i>et al.</i> , "Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme," <i>Biochemistry</i> 34(13):4346-4353, April 4, 1995.
	C56	Frankel and Young, "HIV-1: fifteen proteins and an RNA," <i>Annu. Rev. Biochem.</i> , 67:1-25, 1998.
	C57	Gibbons <i>et al.</i> , "Thy/Liv-SCID-Hu mice implanted with human intestine: an <i>in vivo</i> model for investigation of mucosal transmission of HIV," <i>Aids Res. and Hum. Retrovir.</i> , 13:1453-1460, 1997.
	C58	Glenn <i>et al.</i> , "Skin immunization made possible by cholera toxin," <i>Nature</i> , 391:851, 1998.
	C59	Gotch <i>et al.</i> , "New observations on cellular immune responses to HIV and T-cell epitopes," <i>Aids</i> , 11:S99-S107, 1997.
	C60	Graham and Wright, "Drug therapy, candidate aids vaccines," <i>Drug Ther.</i> , 333:1331-1339, 1995.
	C61	Guidotti, <i>et al.</i> , "Viral clearance without destruction of infected cells during acute HBV infection," <i>Science</i> , 284:825-829, 1999.
	C62	Hahn, "Viral Genes and Their Products," <i>Textbook of AIDS Medicine</i> , Chapter 3, pp. 21-43, Brother <i>et al.</i> , eds., Williams & Wilkens, Baltimore, MD, 1994.
	C63	Hargrave <i>et al.</i> , "Novel non-nucleoside inhibitors of hiv-1 reverse transcriptase, 1. tricyclic pyridobenzo- and dipyrindodiazepinones," <i>J. of Med. Chem.</i> , 34:2231-2241, 1991.
	C64	Harouse, <i>et al.</i> , "Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs," <i>Science</i> , Internet: www.sciencemag.org, 1999.
	C65	Ho, "Toward HIV eradication or remission: the tasks ahead," <i>Science</i> , 280:1866-1867, 1998.

25356361.1

EXAMINER:

DATE CONSIDERED:

10/01/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

RIOS:004USC2

Serial No.

10/667,534

List of Patents and Publications for Applicant's

Applicant

Adan Rios

INFORMATION DISCLOSURE STATEMENT

Filing Date:

September 22, 2003

Group:

Unknown 1648

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C66	Hong <i>et al.</i> , "Discovery of HIB-1 integrase inhibitors by pharmacophore searching," <i>J. Med. Chem.</i> , 40:930-936, 1997, Abstract.
	C67	Huang <i>et al.</i> , "Effect of mutations in the nucleocapsid protein (NCP7) upon PR160(GAG-POL) and trna (lys) incorporation into human immunodeficiency virus type 1," <i>J. of Virology</i> , 71(6):4378-4384, 1997, Abstract.
	C68	Huston, "The biology of the immune system," <i>JAMA</i> , 278:1804-1813, 1997.
	C69	Jawetz eds., <i>et al.</i> , "Serologic diagnosis & immunologic detection of virus infections," <i>Lange Medical Book</i> , 17th ed., Appleton & Lange, Norwalk, CT, pp. 371-380, 1987.
	C70	Jing <i>et al.</i> , "Potassium-induced loop conformational transition of a potent anti-HIV oligonucleotide," <i>J. Biomol Struct. Dyn.</i> , 15:573-583, 1997, Abstract.
	C71	Jockusch <i>et al.</i> , "Photo-induced inactivation of viruses: adsorption of methylene blue, thionine, and thiopyronine on Q $\beta$ bacteriophage," <i>Proc. Natl. Acad. Sci. USA</i> , 93:7446-7451, 1996.
	C72	Kim <i>et al.</i> , "Limitation of Hu-PBL-scid mouse model in direct application to immunotoxicity assessment," <i>J. Pharmacol Toxicol Methods</i> , 37:83-89, 1997 (Abstract).
	C73	Knight and Patterson, "Bone marrow-derived dendritic cells, infection with human immunodeficiency virus, and immunopathology," <i>Annu. Rev. Immunol.</i> , 15:593-615, 1997.
	C74	Kollmann <i>et al.</i> , "Disseminated human immunodeficiency virus 1 (hiv-1) infection in scid-hu mice after peripheral inoculation with hiv-1," <i>J. Exp. Med.</i> , 179:513-522, 1994.
	C75	Korber, <i>et al.</i> , "Limitations of a molecular clock applied to considerations of the origin of HIV-1," <i>Science</i> , 280:1868-1871, 1998.
	C76	LaCasse <i>et al.</i> , "Fusion-competent vaccines: broad neutralization of primary isolates of HIV," <i>Science</i> , 283:357-362, 1999.
	C77	Lamb-Wharton <i>et al.</i> , "Primate models of AIDS vaccine development," <i>Aids</i> , 11(suppl A):S121-S126, 1997.
	C78	Lanzavecchia, "Licence to kill," <i>Nature</i> , 393:413-414, 1998.
	C79	Letvin, "Progress in the development of an HIV-1 vaccine," <i>Science</i> , 280:1875-1880, 1998.
	C80	Letvin, "Vaccines against human immunodeficiency virus -- progress and prospects," <i>N.E. J. of Med.</i> , 329:1400-1405, 1993.

25356361.1

EXAMINER:

DATE CONSIDERED:

12/01/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

RIOS:004USC2

Serial No.

10/667,534

List of Patents and Publications for Applicant's

Applicant

Adan Rios

INFORMATION DISCLOSURE STATEMENT

Filing Date:

September 22, 2003

Group:

Unknown 1648

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C81	Lin <i>et al.</i> , "Photoaffinity labeling by 4-thiodideoxyuridine triphosphate of the HIV-1 reverse transcriptase active site during synthesis," <i>J. Bio. Chem.</i> , 273:997-1002, 1998.
	C82	Loetscher <i>et al.</i> , "CCR5 is characteristic of Th1 lymphocytes," <i>Nature</i> , 391:344-345, 1998.
	C83	Long, "Signal sequences stop killer cells," <i>Nature</i> , 391:740-741, 1998.
	C84	Luster, "Chemokines - chemotactic cytokines that mediate inflammation," <i>New Engl. J. of Med.</i> , 338:436-445, 1998.
	C85	Martinez, "Positive + Positive: Sex and the risk of reinfection," <i>Center for AIDS Hope &amp; Remembrance</i> , 3(6):3-5, 1997.
	C86	Matthews <i>et al.</i> , "Preliminary studies of photoinactivation of human immunodeficiency virus in blood," <i>Transfusion</i> , 31:636-641, 1991.
	C87	Mazumder <i>et al.</i> , "Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action," <i>J. Med. Chem.</i> , 40:3057-3063, 1997, Abstract.
	C88	McIntosh and Burchett, "Clearance of HIV-lessons from newborns," <i>The New Engl. J. of Med.</i> , 332:883-884, 1995.
	C89	McMichael and Phillips, "Escape of human immunodeficiency virus from immune control," <i>Annu. Rev. Immunol.</i> , 15:271-296, 1997.
	C90	Meldorf and Corey, "HIV vaccines: combination and prime-boost strategies," <i>HIV</i> , Vol. 7, No. 1, pp. 24-29.
	C91	Montefiori and Moore, "Magic of the occult?," <i>Science</i> , 283:336-337, 1999.
	C92	Murphy <i>et al.</i> , "The huPBL-SCID mouse as a means to examine human immune function in vivo," <i>Semin Immunol</i> , 8:233-241, 1996 (Abstract).
	C93	Musey <i>et al.</i> , "Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection," <i>The New England J. of Med.</i> , 337:1267-1274; 1305-1308, 1997.
	C94	Namikawa <i>et al.</i> , "Infection of the SCID-hu mouse by HIV-1," <i>Science</i> , 242:1684-1686, 1988.
	C95	NIMH Trial Group, "The NIMH multisite HIV prevention trial: reducing HIV sexual risk behavior," <i>Science</i> , 280:1889-1894, 1998.

25356361.1

EXAMINER:

DATE CONSIDERED:

10/1/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket N . RIOS:004USC2	Serial N . 10/667,534
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Adan Rios	
		Filing Date: September 22, 2003	Group: <del>Unknown</del> 1648
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Ref. Des.	Citation
C96	Pamer and Cresswell, "Mechanisms of MHC class I-restricted antigen processing," <i>Annu. Rev. Immunol.</i> , 16:323-358, 1998.
C97	Pantaleo <i>et al.</i> , "Studies in subjects with long-term nonprogressive human immunodeficiency virus infection," <i>N. Engl. J. Med.</i> , 332(4):209-216, 1995.
C98	Pauwels <i>et al.</i> , "Potent and selective inhibition of HIV-1 replication <i>in vitro</i> by a novel series of TIBO derivatives," <i>Letters To Nature</i> , 343:470-474, 1990.
C99	Peeters <i>et al.</i> , "Virological and polymerase chain reaction studies of HIV-1/HIV-2 dual infection in Côte d'Ivoire," <i>Lancet</i> , 340:339-340, 1992.
C100	Perrin and Telenti, "HIV treatment failure: testing for HIV resistance in clinical practice," <i>Science</i> , 280:1871-1873, 1998.
C101	Phoolcharoen, "HIV/aids prevention in Thailand: success and challenges," <i>Science</i> , 280:1873-1874, 1998.
C102	Quinn, "Acute primary HIV infection," <i>JAMA</i> , 278:58-62, 1997.
C103	Ren <i>et al.</i> , "Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives," <i>Biochem.</i> , 37:14394-14403, 1998.
C104	Ridge <i>et al.</i> , "A conditioned dendritic cell can be a temporal bridge between a CD4 <sup>+</sup> T-helper and a T-killer cell," <i>Nature</i> , 393:473-483, 1998.
C105	Robinson, "DNA vaccines for immunodeficiency viruses," <i>Aids</i> , 11:S109-S119, 1997.
C106	Robinson, "L-chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the <i>in vitro</i> anti-HIV-1 effect of zidovudine plus a protease inhibitor (AG1350)," <i>Antiviral Res.</i> , 39:101-111, 1998, Abstract.
C107	Rosenberg <i>et al.</i> , "Vigorous HIV-1-specific cd4 <sup>+</sup> t cell responses associated with control of viremia," <i>Science</i> , 278:1447-1450, 1997.
C108	Rossio <i>et al.</i> , "Inactivation of Human Immunodeficiency Virus Type 1 Infectivity with Preservation of Conformational and Functional Integrity of Virion Surface Patterns," <i>J. Virology</i> , 72(10):7992-8001, 1998.
C109	Roth <i>et al.</i> , "Synthesis and biological activity of novel nonnucleoside inhibitors of hiv-1 reverse transcriptase. 2-aryl-substitued benzimidazoles," <i>J. of Med. Chem.</i> , 40:4199-4205, 1997.

25356361.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)

Atty. Docket No.  
RIOS:004USC2Serial No.  
10/667,534

List of Patents and Publications for Applicant's

Applicant  
Adan Rios

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
September 22, 2003Gr up:  
~~Unknown~~ 1648U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C110	Schacker <i>et al.</i> , "Annals of internal medicine, biological and virologic characteristics of primary HIV infection," <i>Ann. Intern. Med.</i> , 128:613-620, 1998.
	C111	Schmitz <i>et al.</i> , "Control of viremia in simian immunodeficiency virus infection by cd8 <sup>+</sup> lymphocytes," <i>Science</i> , 283:857-860, 1999.
	C112	Schultz, "Changing paradigms for an HIV vaccine," <i>In: Adv. in Exper. Med. and Biol.</i> , 397:79-90, 1996.
	C113	Schumacher, "Immunology: accessory to murder," <i>Nature</i> , 398:26-27, 1999.
	C114	Sigal <i>et al.</i> , "Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen," <i>Nature</i> , 398:77-80, 1999.
	C115	Smart, "The first integrase inhibitor," <i>GMHC Treat Issues</i> , 10:8-9, 1996, Abstract.
	C116	Smerdon <i>et al.</i> , "Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1," <i>Proc. Natl. Acad. Sci., USA</i> , 91:3911-3915, 1994.
	C117	Suhadolnik <i>et al.</i> , "Photolabeling of the enzymes of the 2-5A synthetase/RNase L/p68 kinase antiviral systems with azido probes," <i>Progress in Molecular and Subcellular Biology</i> 14:260-275, 1994.
	C118	Sylwester <i>et al.</i> , "CD4 <sup>+</sup> T-Lymphocyte Depletion in Human Lymphoid Tissue Ex Vivo Is Not Induced by Noninfectious Human Immunodeficiency Virus Type 1 Virions," <i>J. Virology</i> , 72(11):9345-9347, 1998.
	C119	Tang and Cyster, "Chemokine up-regulation and activated T cell attraction by maturing dendritic cells," <i>Science</i> , 284:819-822, 1999.
	C120	Tarasiev <i>et al.</i> , "Photochemoinactivation: a way to AIDS vaccine?," <i>America Online: ARIOS927</i> , Vol. 9 Issue/Part/Supplement 1, 1993 (Abstract).
	C121	Walker, "Immunopathogenesis and immune reconstitution in HIV disease," <i>Intl. Aids Soc.-USA</i> , 6:4-7, 1999.
	C122	Wallace <i>et al.</i> , "Preclinical pharmacology of an anti-HIV oligonucleotide," <i>Int. Conf. AIDS</i> , 11:314, 1996, Abstract.
	C123	Watts, "Capture and processing of exogenous antigens for presentation on MHC molecules," <i>Annu. Rev. Immunol.</i> , 15:821-850, 1997.

25356361.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial N .

RIOS:004USC2

10/667,534

List of Patents and Publications for Applicant's

Applicant

Adan Rios

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

September 22, 2003

Group:

Unknown 1648

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C124	Wu <i>et al.</i> , "A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site," <i>Biochem.</i> , 30:2022-2026, 1991.
	C125	Wyatt and Sodroski, "The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens," <i>Science</i> , 280:1884-1888, 1998.
	C126	Yang <i>et al.</i> , "Neutralizing antibodies against hiv determined by amplification of viral long terminal repeat sequences from cells infected in vitro by nonneutralized virions," <i>J. of Acq. Imm. Defic. Synd. and Hum. Retro.</i> , 17:27-34, 1998.
	C127	Zhang <i>et al.</i> , "Nascent Human Immunodeficiency Virus Type 1 Reverse Transcription Occurs within an Enveloped Particle," <i>J. Virology</i> , 69(6):3675-3682, 1995.
	C128	Zhao, <i>et al.</i> , "Hydrazide-containing inhibitors of HIV-1 integrase," <i>J. Med. Chem.</i> , 40:937-941, 1997, Abstract.
	C129	Zinkernagel and Doherty, "Immunological surveillance against altered self components by sensitized T lymphocytes in lymphocytic choriomeningitis," <i>Nature</i> , 251:547-548, 1974.
	C130	Zinkernagel and Doherty, "MHC-restricted cytotoxic t cells: studies on the biological role of polymorphic major transplantation antigens determining t-cell restriction-specificity, function, and responsiveness," <i>Advan. In Immunol.</i> , New York, Academic Press, 27:51-177, 1979.
	C131	Zinkernagel and Doherty, "Restriction of <i>in vitro</i> T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system," <i>Nature</i> , 248:701-702, 1974.
	C132	PCT Search Report dated July 7, 1999

25356361.1

EXAMINER:

DATE CONSIDERED:

10/10/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)